Advertisement

Journal of Neuro-Oncology

, Volume 92, Issue 1, pp 57–63 | Cite as

Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma

  • T. MikkelsenEmail author
  • T. Doyle
  • J. Anderson
  • J. Margolis
  • N. Paleologos
  • J. Gutierrez
  • D. Croteau
  • L. Hasselbach
  • R. Avedissian
  • L. Schultz
Clinical study - patients study

Abstract

The treatment of patients with anaplastic oligodendroglioma (AO) has been significantly impacted by the molecular detection of loss of sequences on chromosomes 1p and 19q. We performed a clinical trial to prospectively evaluate the safety of treating patients with AO with temozolomide (TMZ) alone in patients with chromosome 1p/19q loss and with chemo-radiation in patients not harboring this loss. Forty-eight patients were enrolled, 36/48 (75%) with evidence of chromosome 1p/19q loss treated with TMZ alone and 12/18 (25%) without such losses, treated with pre-radiation TMZ followed by chemo-radiation. Despite more aggressive treatment, patients without 1p/19q loss had a shorter progression-free survival (PFS) of 13.5 months. With a median follow-up time of 32 months, patients with 1p/19q LOH had a median TTP of 28.7 months. Patients with AO with 1p/19q LOH can be safely treated with single-agent TMZ and do not appear to experience earlier or more frequent tumor progression. This treatment regimen should be studied as part of a formal randomized clinical trial.

Keywords

Temozolomide Single-agent chemotherapy Anaplastic oligodendroglioma 

Notes

Disclosure

Conflicts of interest – research support was provided by Schering.

References

  1. 1.
    Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. doi: 10.1093/jnci/90.19.1473 PubMedCrossRefGoogle Scholar
  2. 2.
    Ino Y, Betensky RA, Zlatescu MC et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845PubMedGoogle Scholar
  3. 3.
    Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861. doi: 10.1158/0008-5472.CAN-06-1796 PubMedCrossRefGoogle Scholar
  4. 4.
    Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714. doi: 10.1200/JCO.2005.04.3414 PubMedCrossRefGoogle Scholar
  5. 5.
    van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24:2715–2722. doi: 10.1200/JCO.2005.04.6078 PubMedCrossRefGoogle Scholar
  6. 6.
    Mohile N, Forsyth P, Stewart D et al (2008) A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol 89:187–193. doi: 10.1007/s11060-008-9603-8 PubMedCrossRefGoogle Scholar
  7. 7.
    Kouwenhoven MC, Kros JM, French PJ et al (2006) 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42:2499–2503. doi: 10.1016/j.ejca.2006.05.021 PubMedCrossRefGoogle Scholar
  8. 8.
    Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79:153–157. doi: 10.1007/s11060-005-9020-1 PubMedCrossRefGoogle Scholar
  9. 9.
    Abrey LE, Louis DN, Paleologos N et al (2007) Oligodendroglioma study G: survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 9:314–318. doi: 10.1215/15228517-2007-002 PubMedCrossRefGoogle Scholar
  10. 10.
    Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  11. 11.
    Bogler O, Newsham I (2002) Studying the heterogeneity of brain tumors using medium throughput LOH analysis. Cytometry 47:52–55. doi: 10.1002/cyto.10035 PubMedCrossRefGoogle Scholar
  12. 12.
    Cairncross J, Macdonald D, Ramsay D (1992) Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 3:78–82CrossRefGoogle Scholar
  13. 13.
    Bryant J, Day R (1995) Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372–1383. doi: 10.2307/2533268 PubMedCrossRefGoogle Scholar
  14. 14.
    Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ (2007) A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87:392–397PubMedGoogle Scholar
  15. 15.
    Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354. doi: 10.1056/NEJM200011093431901 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • T. Mikkelsen
    • 1
    • 2
    • 3
    Email author
  • T. Doyle
    • 1
    • 6
  • J. Anderson
    • 1
    • 6
  • J. Margolis
    • 7
  • N. Paleologos
    • 8
  • J. Gutierrez
    • 1
    • 5
  • D. Croteau
    • 1
  • L. Hasselbach
    • 1
    • 3
  • R. Avedissian
    • 1
  • L. Schultz
    • 2
    • 3
    • 4
  1. 1.Hermelin Brain Tumor CenterHenry Ford Health SystemDetroitUSA
  2. 2.Department of NeurologyFord HospitalDetroitUSA
  3. 3.Department of NeurosurgeryFord HospitalDetroitUSA
  4. 4.Department of Biostatistics and Research EpidemiologyFord HospitalDetroitUSA
  5. 5.Department of PathologyFord HospitalDetroitUSA
  6. 6.Department of Medical OncologyHenry Ford HospitalDetroitUSA
  7. 7.Department of Medical OncologyWilliam Beaumont HospitalRoyal OakUSA
  8. 8.Department of NeurologyEvanston HospitalEvanstonUSA

Personalised recommendations